GCO — Genesco Inc. — heads into the final day of April with a familiar tension: short sellers are rebuilding after a brief retreat, the stock has given back nearly 6% on the week despite a 24% surge over the prior month, and the CEO herself sold shares just as the rally was gaining momentum.
The short interest picture is the most coherent thread this week. Shorts are running at 10% of the free float — a level that has held stubbornly throughout April and up from around 8.7% in mid-March. The trend matters: that 15-percentage-point climb in SI % FF since late March reflects a deliberate, sustained rebuild, not noise. The one-day tick higher to 10.04% on April 28 adds to the pattern. Official FINRA data, settled through April 15, confirmed 838,143 shares short with days to cover at 2.47 — broadly consistent with the daily estimates. This is not a stock where bears are capitulating, even after a 24% monthly rally.
The borrow market, though, gives short sellers little to complain about. Availability remains wide. Cost to borrow has stayed around 0.44% all month — it briefly spiked above 0.55% during the early April volatility wave but quickly retraced. With SI utilization at just 9.3% against a 52-week high of 23%, there is ample room for further short building without any lending squeeze. Options tell a slightly more cautious story. The put/call ratio is running at 18.2, just above its 20-day average of 17.6 and roughly one standard deviation elevated, suggesting a mild bias toward downside protection. That's far from the panic-PCR territory of 22.6 seen in late March, but the directional lean is still defensive.
The insider angle deserves attention. On April 2 — with the stock trading around $28.39 — CEO Mimi Vaughn sold 22,583 shares worth roughly $641,000. She was joined by four other executives selling that same day, collectively offloading the equivalent of just under $280,000 across the SVP and divisional president ranks. These were all low-significance filings, and some likely reflect pre-arranged plans, but the cluster is hard to ignore: five insiders selling in a single session, right at the start of what became a 22% rally into the month-end. Vaughn still holds 450,328 shares (4.15% of the company), giving her significant continued alignment, but the April 2 print is now visibly below the current price of $34.58.
On the fundamental side, the Street is cautious and somewhat stale. The most recent analyst action with any recency came from Truist Securities in early March, where the firm cut its price target from $38 to $32 while staying at Hold — the third consecutive trim from the same analyst over the past year. The mean consensus target is $36.00, which represents only 1.7% upside from current levels. That leaves GCO trading almost exactly in line with where the Street thought it ought to be priced a few weeks ago, before the April rally closed the gap. Bulls point to the Journeys segment's near double-digit comparable sales growth and an upward revision to the FY2026 sales outlook to 3-4%. Bears flag gross margin pressure — projected to contract 50-70 basis points this quarter — and structural headwinds at the UK Schuh segment. The P/E has re-rated meaningfully over the month, expanding by roughly 2 turns to 14.8x, while EV/EBITDA has ticked down to 11.5x as the enterprise value reprices. The RSI at 70.6 suggests the stock is now technically extended.
EPS momentum is one of the few genuinely bright spots in the factor profile. The 90-day EPS momentum rank is at the 97th percentile, and the 30-day reading is at 72. The earnings surprise rank at the 81st percentile suggests Genesco has been a consistent beat story. The next test comes on June 5, when Q4 FY2026 results are due. The last print in March produced a muted day-one reaction of -0.77%, which expanded to a -4.1% move over the subsequent five sessions — a pattern of initial resilience followed by a longer digest.
Peers had a rough week, broadly. BBW fell 7.3% and FND dropped 7.8% — both underperforming GCO's -6% weekly slide. CURV was the worst of the group, down 25%. That relative outperformance provides some context for GCO's hold near $34, but with short interest elevated, insider sales sitting in recent memory, and the Street's price target now essentially met, the June earnings call is the next real pivot point to watch.
See the live data behind this article on ORTEX.
Open GCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
